Study aim: The effect of zinc on the treatment and clinical course of patients with SARS-cov2 (COVID-19) Design: Clinical trial with control group, with parallel, randomized groups, phase 2-3 on 80 patients. The Random Sample of Cases menu of spss software was used for randomization. Settings and conduct: At Amin Hospital in Isfahan, 80 patients with COVID-19 were selected and the demographic and clinical information of the subjects included, including age, sex, initial diagnosis (cause of hospitalization), underlying disease, WBC count, ESR and CRP and LDH levels, CT scan Lung and RT PCR will be recorded for all patients prior to hospitalization. The diagnostic criterion for COVID-19 in patients to enter the study is pulmonary involvement in CT scan of the lung with RT PCR test. Participants/Inclusion and exclusion criteria: Inclusion: 18 years of age or older Diagnosis of COVID-19 by RT PCR and CT scan of the lungs Blood oxygen levels are between 90 and 93 percent Breathing rate between 20 and 24 per minute Heart rate between 100 and 130 beats per minute Exclusion: Intubation (mechanical ventilation) Blood oxygen level below 90% Breathing rate equal to 30 or more per minute Allergic reaction to drugs Shortness of breath caused by cardiogenic pulmonary edema Pregnancy and lactation History of oxygen therapy at home Patients with end stage, lung, malignant, G6PD deficiency, diabetic ketoacidosis, cardiac arrhythmia. Intervention groups: The control group included 40 patients with COVID-19 who were given two hydroxychloroquine sulfate tablets of 200 mg every 12 hours on the first day and then 200 mg every 12 hours. For the intervention group (40 people), in addition to the above, zinc tablets with a dose of 220 mg twice daily will be administered orally during the patient's hospital stay. Main outcome variables: Clinical response; Mortality; hospital stay